Start here if you're new
what it is
Balchem sells the tiny ingredients and sterilization chemicals that make food, supplements, animal feed, and medical products actually work.
how it gets paid
Last year Balchem made $1.0B in revenue.
why it's growing
Revenue grew 293.4% last year. Gross margin at 35.6% matters most because margin expansion is doing a lot of the heavy lifting while revenue grows just 10%.
what just happened
Balchem put up $264M in quarterly revenue, up 10% vs. prior year, while EPS rose 17% to $1.21.
At a glance
A balance sheet — strong enough to weather a downturn
95/100 earnings predictability — you can trust these numbers
35.9x trailing p/e — you're paying up for this one
0.7% dividend yield — cash in your pocket every quarter
9.5% return on capital — nothing to write home about
xvary composite: 74/100 — average
What they do
Balchem sells the tiny ingredients and sterilization chemicals that make food, supplements, animal feed, and medical products actually work.
Balchem lives in the small parts of products that customers do not want failing. Human Nutrition & Health was 63% of 2024 sales, and once your formula depends on a specialty ingredient, switching costs (changing suppliers is expensive and risky) show up fast. You do not rip out a proven ingredient to save a little money when your own product quality is on the line.
How they make money
$1.0B
annual revenue · their business grew +293.4% last year
total revenue
$1.0B
+293.4%
The products that matter
core earnings base
human nutrition ingredients
part of a roughly $1.0B revenue company
This is the steady part of the story. For you as a shareholder, the appeal is repeat demand and margin discipline, not some sudden revenue explosion.
cash-generating core
higher-value technology
microencapsulation tech
the multiple says this matters
BCPC trades at 35.9x earnings while sales growth sits at 5.5%. That only works if higher-value offerings keep protecting margins and mix. Otherwise you are paying a premium for a normal manufacturer.
margin lever
regulated process exposure
medical sterilization
one of the real swing factors
The business uses ethylene oxide and propylene oxide for sterilization. That makes regulation a live operating variable even though the finances look clean. Balance-sheet safety does not erase process risk.
regulatory watch
Key numbers
35.9x
trailing p/e
P/E (price divided by earnings) → how expensive the stock is → so what: you are paying a premium price for a mid-single-digit sales grower.
25.0%
operating margin
Operating margin (profit after running the business) → how efficient operations are → so what: Balchem converts a quarter of sales into operating profit.
9.5%
return on capital
Return on capital (profit earned on money invested) → how productive management is with your cash → so what: good, but not elite for this valuation.
$154M
long-term debt
Debt is just 3% of capital, which means the balance sheet has room if the company wants to invest or absorb a rough patch.
Financial health
A
strength
- balance sheet grade A — very strong financial position
- risk rank 2 — safer than 80% of stocks
- price stability 90 / 100
- long-term debt $154M (3% of capital)
- net profit margin 14.8% — keeps 15 cents of every dollar in revenue
- return on equity 10% — $0.10 profit for every $1 investors have put in
A — among the top-rated companies for balance sheet quality.
Total return vs. market
You invested $10,000 in BCPC 3 years ago → it's now worth $13,030.
The index would have given you $13,880.
source: institutional data · total return
What just happened
beat estimates
Balchem put up $264M in quarterly revenue, up 10% vs. prior year, while EPS rose 17% to $1.21.
The clean part is that profit grew faster than sales. Management's cost controls and productivity work helped push earnings ahead of the top-line increase.
$264M
revenue
$1.21
eps
35.6%
gross margin
the number that mattered
Gross margin at 35.6% matters most because margin expansion is doing a lot of the heavy lifting while revenue grows just 10%.
-
cost controls and productivity improvements ought to have bolstered margins, as well.
-
in all, earnings per share likely jumped 22%, vs. prior year, on a 7% sales advance.
-
the company is well positioned for near-term gains.
-
based on the above actions, we think share earnings and sales will probably advance between 5% and 10% this year.
-
the top and bottom lines ought to expand at a low- to mid-single-digit clip in 2027.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
BCPC's main risk is not debt or basic financial stress. It is that a premium multiple meets a business with real operating and regulatory pressure points, especially around sterilization chemistry and margin dependence.
med
sterilization chemistry regulation
The company uses ethylene oxide and propylene oxide for sterilization. Those chemicals face health-risk scrutiny, which means regulation can move from abstract headline to plant-level constraint fast.
If rules tighten in a way that affects throughput, compliance costs, or site operations, the medical sterilization piece becomes an earnings issue instead of a footnote.
med
premium multiple meets ordinary growth
BCPC trades at 35.9x earnings while sales growth is 5.5%. That works when execution is clean and investors keep paying for predictability. It works a lot less well if growth looks merely fine.
If the business settles into the low- to mid-single-digit 2027 view without stronger margin support, multiple compression does more damage than the business itself.
med
earnings are relying on margin work
A recent setup of 22% EPS growth on a 7% sales gain says profitability is scaling faster than revenue. That is great news if productivity keeps showing up. It is a problem if that spread narrows.
If earnings stop outrunning sales, the stock loses one of the few things justifying a premium p/e in a modest-growth business.
med
weak momentum removes your cushion
Momentum rank 5 is the ugliest number on the page. In plain English: the market is not treating BCPC like a leader right now even though the underlying company looks disciplined.
If results are only okay, you do not have trend support underneath the stock. That raises the odds of a sharper reaction to any disappointment.
The business looks sturdy. The stock only stays sturdy if Balchem keeps delivering high-single-digit growth without a margin slip.
source: institutional data · regulatory filings · risk analysis
Pay attention to
growth
Whether BCPC stays above the low-single-digit long view
Analysts still see 5–10% sales and earnings growth this year, but the 2027 view cools back to low- to mid-single digits. That gap is the whole valuation debate.
regulation
Sterilization chemistry headlines that become operating constraints
Ethylene oxide and propylene oxide already sit under scrutiny. If that pressure turns into tighter operating rules, the quality story gets more complicated fast.
margin
Whether EPS keeps outrunning sales
A recent setup of 22% EPS growth on a 7% sales gain says margins did a lot of work. Watch whether that spread holds or starts closing.
earnings
The next quarter's proof point near the 52-week high
Latest quarter EPS was $1.21, up 17% from a year ago. For a stock trading near $176 highs, merely decent numbers may not be enough.
Analyst rankings
short-term outlook
average
outlook rank 3 — in human-speak, analysts think BCPC should behave roughly like the broader market over the next stretch.
risk
above average
risk rank 2 — safer than roughly 80% of stocks. You own quality here, even if you are not buying it cheap.
momentum
bottom 5%
momentum rank 5 — the market has been treating this as a laggard, not a leader.
predictability
95 / 100
management's guidance is usually reliable. Few surprises help quality investors and leave less room for a dramatic rerating story.
source: institutional data
Institutional activity
182 buyers vs. 182 sellers in 3q2025. total institutional holdings: 29.0M shares.
source: institutional data
Price targets
3-5 year target range
$147
$256
$172
current price
$202
target midpoint · +17% from current · 3-5yr high: $285 (+65% · 14% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive